CN101511345A - 凝血酶受体拮抗剂的即释片剂 - Google Patents

凝血酶受体拮抗剂的即释片剂 Download PDF

Info

Publication number
CN101511345A
CN101511345A CNA2007800325694A CN200780032569A CN101511345A CN 101511345 A CN101511345 A CN 101511345A CN A2007800325694 A CNA2007800325694 A CN A2007800325694A CN 200780032569 A CN200780032569 A CN 200780032569A CN 101511345 A CN101511345 A CN 101511345A
Authority
CN
China
Prior art keywords
formulation
pharmaceutical formulation
compound
weight
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800325694A
Other languages
English (en)
Chinese (zh)
Inventor
R·古塔
S·查德瑞
S·S·道吉雷拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Priority to CN201510409546.7A priority Critical patent/CN104922054A/zh
Publication of CN101511345A publication Critical patent/CN101511345A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2007800325694A 2006-06-30 2007-06-29 凝血酶受体拮抗剂的即释片剂 Pending CN101511345A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510409546.7A CN104922054A (zh) 2006-06-30 2007-06-29 凝血酶受体拮抗剂的即释片剂

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81782106P 2006-06-30 2006-06-30
US60/817,821 2006-06-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510409546.7A Division CN104922054A (zh) 2006-06-30 2007-06-29 凝血酶受体拮抗剂的即释片剂

Publications (1)

Publication Number Publication Date
CN101511345A true CN101511345A (zh) 2009-08-19

Family

ID=38895141

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2007800325694A Pending CN101511345A (zh) 2006-06-30 2007-06-29 凝血酶受体拮抗剂的即释片剂
CN201510409546.7A Pending CN104922054A (zh) 2006-06-30 2007-06-29 凝血酶受体拮抗剂的即释片剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510409546.7A Pending CN104922054A (zh) 2006-06-30 2007-06-29 凝血酶受体拮抗剂的即释片剂

Country Status (18)

Country Link
US (2) US20080031943A1 (https=)
EP (2) EP2034969B1 (https=)
JP (2) JP5116764B2 (https=)
KR (1) KR20090023670A (https=)
CN (2) CN101511345A (https=)
AR (1) AR061790A1 (https=)
AU (1) AU2007269733B2 (https=)
BR (1) BRPI0713935A2 (https=)
CA (1) CA2656395C (https=)
CL (1) CL2007001923A1 (https=)
CO (1) CO6150126A2 (https=)
ES (2) ES2616354T3 (https=)
MX (1) MX2009000131A (https=)
NO (1) NO20090467L (https=)
PE (1) PE20080376A1 (https=)
TW (1) TWI367112B (https=)
WO (1) WO2008005353A2 (https=)
ZA (1) ZA200900350B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102442965A (zh) * 2010-09-30 2012-05-09 天津药物研究院 用于治疗血栓性疾病的par-1拮抗剂及其制备方法和用途
CN111670035A (zh) * 2018-02-02 2020-09-15 尤斯特拉里斯制药有限公司（以普雷舒拉纽罗作为商号） 经口制剂及其用途

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
WO2008079260A2 (en) * 2006-12-22 2008-07-03 Schering Corporation Disintegration promoters in solid dose wet granulation formulations
US8624050B2 (en) * 2007-06-22 2014-01-07 General Electric Company Solution process for transparent conductive oxide coatings
WO2009078999A1 (en) 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
ES2437100T3 (es) 2009-06-04 2014-01-08 Merck Sharp & Dohme Corp. Metabolito activo de un antagonista de los receptores de la trombina
MX2011013091A (es) 2009-06-08 2012-01-12 Schering Corp Un antagonista del receptor de trombina y tableta con dosificacion fija de clopidogrel.
TR201601548A2 (tr) 2016-02-05 2018-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu
WO2017134200A1 (en) 2016-02-05 2017-08-10 Sanovel Ilac Sanayi Ve Ticaret A.S. A novel pharmaceutical composition of vorapaxar and metoprolol

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61137813A (ja) * 1984-12-07 1986-06-25 Sawai Seiyaku Kk 持続性セフラジン製剤
JPS63162620A (ja) * 1986-12-25 1988-07-06 Teisan Seiyaku Kk 遅溶性顆粒及びそれを用いた持続性複合顆粒
GB9414045D0 (en) * 1994-07-12 1994-08-31 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
US20010003588A1 (en) * 1996-09-12 2001-06-14 Smithkline Beecham Corporation Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2.]oct-3-yl)acetonitrile monohydrochloride
JPH10130142A (ja) * 1996-10-31 1998-05-19 Zensei Yakuhin Kogyo Kk 放出持続型圧縮製剤
JPH10298062A (ja) * 1997-04-24 1998-11-10 Pfizer Pharmaceut Co Ltd 口腔内速溶型錠剤
US6063847A (en) 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
KR100393492B1 (ko) * 1997-11-25 2003-08-02 쉐링 코포레이션 트롬빈 수용체 길항제
WO2001000656A2 (en) 1999-06-29 2001-01-04 Ortho-Mcneil Pharmaceutical, Inc. Novel indazole peptidomimetics as thrombin receptor antagonists
US6858577B1 (en) 1999-06-29 2005-02-22 Ortho-Mcneil Pharmaceutical, Inc. Indole peptidomimetics as thrombin receptor antagonists
US6630451B1 (en) 1999-06-29 2003-10-07 Orthomcneil Pharmaceutical, Inc. Benzimidazolone peptidometics as thrombin receptor antagonist
US7304078B2 (en) * 2002-04-16 2007-12-04 Schering Corporation Thrombin receptor antagonists
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
ES2291323T3 (es) 2000-06-15 2008-03-01 Schering Corporation Antagonistas de receptores de trombina.
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
JP2005500253A (ja) * 2001-02-23 2005-01-06 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド トロンビン受容体アンタゴニストとしてのアミノメチルピロロキナゾリン化合物
NZ528820A (en) 2001-04-19 2007-01-26 Eisai Co Ltd 2-iminopyrrolidine derivatives
BR0213967A (pt) 2001-10-18 2005-08-30 Schering Corp Análogos de himbacina como antagonistas do receptor de trombina
DE10317816A1 (de) * 2003-04-16 2004-11-04 Claas Selbstfahrende Erntemaschinen Gmbh Feldhäcksler mit positionierbarer Fahrerkabine
CZ300438B6 (cs) * 2003-11-25 2009-05-20 Pliva Hrvatska D.O.O. Zpusob prípravy orální pevné lékové formy s okamžitým uvolnováním úcinné látky obsahující jako úcinnou látku polymorfní formu finasteridu
EP1971336A2 (en) * 2005-12-22 2008-09-24 Shering Corporation Thrombin receptor antagonists as phophylaxis to complications from cardiopulmonary surgery
TW200812619A (en) * 2006-04-06 2008-03-16 Schering Corp TRA combination therapies
WO2008005352A2 (en) * 2006-06-30 2008-01-10 Schering Corporation Solid dose formulations of a thrombin receptor antagonist
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
WO2008079260A2 (en) * 2006-12-22 2008-07-03 Schering Corporation Disintegration promoters in solid dose wet granulation formulations
WO2008118320A1 (en) * 2007-03-23 2008-10-02 Schering Corporation Reduction of adverse events.after percutaneous intervention by use of a thrombin receptor antagonist

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102442965A (zh) * 2010-09-30 2012-05-09 天津药物研究院 用于治疗血栓性疾病的par-1拮抗剂及其制备方法和用途
CN102442965B (zh) * 2010-09-30 2013-12-11 天津药物研究院 用于治疗血栓性疾病的par-1拮抗剂及其制备方法和用途
CN111670035A (zh) * 2018-02-02 2020-09-15 尤斯特拉里斯制药有限公司（以普雷舒拉纽罗作为商号） 经口制剂及其用途

Also Published As

Publication number Publication date
US20170224666A9 (en) 2017-08-10
CN104922054A (zh) 2015-09-23
PE20080376A1 (es) 2008-06-13
AR061790A1 (es) 2008-09-24
ES2616354T3 (es) 2017-06-12
US20080031943A1 (en) 2008-02-07
KR20090023670A (ko) 2009-03-05
EP2491922B1 (en) 2017-01-04
BRPI0713935A2 (pt) 2012-12-04
JP2009542678A (ja) 2009-12-03
NO20090467L (no) 2009-03-19
TWI367112B (en) 2012-07-01
MX2009000131A (es) 2009-01-26
US20160193196A1 (en) 2016-07-07
WO2008005353A2 (en) 2008-01-10
ES2616405T3 (es) 2017-06-13
JP2012126752A (ja) 2012-07-05
JP5116764B2 (ja) 2013-01-09
EP2491922A1 (en) 2012-08-29
CL2007001923A1 (es) 2008-02-08
CA2656395A1 (en) 2008-01-10
CA2656395C (en) 2016-12-13
ZA200900350B (en) 2010-01-27
EP2034969A2 (en) 2009-03-18
CO6150126A2 (es) 2010-04-20
EP2034969B1 (en) 2017-01-11
WO2008005353A3 (en) 2008-06-26
TW200810792A (en) 2008-03-01
AU2007269733B2 (en) 2013-02-21
AU2007269733A1 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
JP5116764B2 (ja) トロンビン受容体拮抗薬の即放性錠剤製剤
BR112020024107A2 (pt) combinação farmacêutica, composição, e preparação de combinação que compreende ativador de glucoquinase e inibidor de sglt-2 e métodos de preparação e uso dos mesmos
EP3313187B1 (en) Sustained release formulation and tablets prepared therefrom
NO341027B1 (no) Tablett med høyt medikamentinnhold og fremgangsmåte for fremstilling derav
WO2010033179A1 (en) Granulates, process for preparing them and pharmaceutical products containing them
JP2000511170A (ja) 医薬組成物
JP2010519200A (ja) シロスタゾールを含む制御放出製剤及びその製造方法
JP6302802B2 (ja) カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤の製造方法
JP2009542677A (ja) トロンビン受容体拮抗薬の固形製剤
US6333361B1 (en) Pharmaceutical composition containing zafirlukast
CN108174596A (zh) 包含8-[(3r)-3-氨基-1-哌啶基]-7-(2-丁炔-1-基)-3,7-二氢-3-甲基-1-[4-甲基-2-喹唑啉基)甲基]-1h-嘌呤-2,6-二酮或其药学上可接受的盐的药物组合物
CN114845704A (zh) 包含西苯唑啉或其盐的药物制剂
WO2024180153A2 (en) Lenvatinib composition with improved bioavailability
JPWO2019230937A1 (ja) 溶出性に優れた経口固形製剤
HK1172571A (en) Immediate-release tablet formulations of a thrombin receptor antagonist
TW202435886A (zh) 米爾維仙(milvexian)醫藥組合物
HK40072164A (en) Pharmaceutical formulation comprising cibenzoline or salt thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: new jersey

Applicant after: Schering Corporation

Address before: new jersey

Applicant before: SCHERING CORP (US)

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: SCHERING CORP (US) TO: MSD CORP.

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20090819